News Contact Us

Novartis’s Zolgensma beats expectations by generating $160Mn

Author : Pankaj Singh | Published Date : 2019-10-24 

Novartis is a leading global healthcare company that reimagines medicine to extend and improve patient's lives. It uses innovative technology and science to treat a few of society's most challenging healthcare diseases. 

The company has introduced a gene therapy dubbed Zolgensma for infants with SMA, which is termed as one of the world’s most expensive drugs. However, Novartis recently revealed that Zolgensma has treated over 100 patients and has plowed in a total of $160 million in the last quarter, outperforming analyst’s expectations.

Apparently, Zolgensma treats spinal muscular atrophy, a devastating and rare neurological disease. It holds a record price tag of $2.1 million, or a yearly cost of $425,000 for the series of five years.

As per Novartis, approximately 99% of SMA (spinal muscular atrophy) patients that were opted for Zolgensma received coverage of one-time therapy, however, few had to grind for an approval process to get the therapy. Moreover, the firm hinted that it had attained huge progress in prominent deals with health plans that cover the therapy.

It added that agreements are in place including nearly 30% of patients covered by Medicaid and roughly 90% of patients insured commercially. 

Since its launch, Zolgensma has been making headlines by setting a record-breaking price tag, followed by a data-manipulation scandal and then the astounding figures from its first quarter. However, the drug has now run into a new issue regarding a concern with its manufacturing. This has delayed Zolgensma’s approval in Japan and the EU.

Speaking on which, Dave Lennon, President of AveXis (Novartis’ gene therapy unit), said Novartis has worked quickly to reassure physicians and patients of Zolgensma’s quality, and the data manipulation scandal had no impact on the treatment’s performance.

As per Vas Narasimhan, CEO, Novartis, regulators from the Japanese and European markets have given a written question and have called for an additional inspection before approving the drug to treat infants with SMA.

Source Credit: https://www.statnews.com/2019/10/22/novartis-gene-therapy-brings-in-160-million-beating-expectations/


About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Sir Richard Branson to contribute £200M to stabilize Virgin Atlantic

Published Date: 2020-07-14         Author: Pankaj Singh

British business magnate Sir Richard Branson had reportedly announced that he intends to contribute a sum of £200 million as part of the £1 billion plan to stabilize Virgin Atlantic without taxpayers’ money. Sources state that he will use the funds raised by selling a £396 mi... Read More

The Electric Cycle Company announces plans to move to bigger premises

Published Date: 2020-07-13         Author: Pankaj Singh

After a successful launch of a £70,000 crowdfunding campaign to renovate its shop and workshop, the Scottish e-bike firm Electric Cycle Company has reportedly announced its plans to move to a 4000 sq. ft., carbon-neutral Edinburgh-based premise, which will be the largest e-bike shop in the UK.... Read More

Cipla launches generic version of Remdesivir at a price of ₹4,000

Published Date: 2020-07-10         Author: Pankaj Singh

Cipla Limited, the multinational pharmaceutical company, has reportedly launched a generic version of the remdesivir drug (Cipremi) at a price of ?4,000 per 100 mg vial, making it among the least priced COVID-19 treatment available across the globe. According to sources familiar with the knowledg... Read More

© 2020 Fractovia. All Rights Reserved